PSI-697 (P-Selectin Inhibitor) is an orally active P-selectin inhibitor with anti-inflammatory and anti-thrombotic effects, useful for studying cardiovascular diseases such as atherosclerosis.

P-selectin:50-125 μM

PSI-697 inhibits the binding of soluble human P-selectin to PSGL-1 in a concentration-dependent manner with IC50=50-125 μM. [1]

In a rat model of surgical inflammation, PSI-697 (50 mg/kg, orally) significantly reduced rolling white blood cell count by 39%
In a rat venous thrombosis model, PS-697 (100 mg/kg, orally) reduced thrombus weight by 18% relative to the carrier (P < 0.05) without prolonged bleeding time.
In a rat model of carotid artery injury, PSI-697 (30 or 15 mg/kg oral) administered 1 hour before arterial injury and once daily thereafter for 13 days resulted in a dose-dependent reduction of 40.2% in the intima/media ratio. [1]
In a venous thrombosis rat stenosis model, PSI-697 (30 mg/kg; The thickening of the intima of the venous wall was significantly reduced by daily oral force-feeding. [2]